{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:35:00Z","timestamp":1782963300253,"version":"3.54.5"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijtb.2026.03.006","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:03:43Z","timestamp":1773504223000},"page":"155-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preclinical approaches in tuberculosis drug development research: Bridging experimental tools and clinical translation"],"prefix":"10.1016","volume":"73","author":[{"given":"Akriti","family":"Gaurav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s44197-025-00360-7","article-title":"Multidrug resistance tuberculosis in the context of co-infection in Ethiopia: a systematic review and meta-analysis","volume":"15","author":"Hailu","year":"2025","journal-title":"Journal of Epidemiology and Global Health"},{"key":"10.1016\/j.ijtb.2026.03.006_bib2","series-title":"The Lancet. Respiratory Medicine","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","author":"Dheda","year":"2017"},{"issue":"Suppl 1","key":"10.1016\/j.ijtb.2026.03.006_bib3","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1093\/cid\/civ426","article-title":"Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"4","key":"10.1016\/j.ijtb.2026.03.006_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0004-2015","article-title":"Animal models of tuberculosis: an overview","volume":"4","author":"Williams","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijtb.2026.03.006_bib5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3389\/fmicb.2017.00717","article-title":"Animal models for tuberculosis in translational and precision medicine","volume":"8","author":"Zhan","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijtb.2026.03.006_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41378-021-00262-1","article-title":"Development of single-cell-level microfluidic technology for long-term growth visualization of living cultures of Mycobacterium smegmatis","volume":"7","author":"Wang","year":"2021","journal-title":"Microsyst Nanoeng"},{"issue":"7","key":"10.1016\/j.ijtb.2026.03.006_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012295","article-title":"Advances in an In vitro tuberculosis infection model using human lung organoids for host-directed therapies","volume":"20","author":"Kim","year":"2024","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.ijtb.2026.03.006_bib8","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/infdis\/jiz020","article-title":"In vitro granuloma models of tuberculosis: potential and challenges","volume":"219","author":"Elkington","year":"2019","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02073-16","article-title":"A bioengineered three-dimensional cell culture platform integrated with microfluidics to address antimicrobial resistance in tuberculosis","volume":"8","author":"Bielecka","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.ijtb.2026.03.006_bib10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3389\/fmicb.2017.00717","article-title":"Animal models for tuberculosis in translational and precision medicine","volume":"8","author":"Zhan","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijtb.2026.03.006_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1223260","article-title":"Animal models for COVID-19 and tuberculosis","volume":"14","author":"Corleis","year":"2023","journal-title":"Front Immunol"},{"issue":"435","key":"10.1016\/j.ijtb.2026.03.006_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai7786","article-title":"Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data","volume":"10","author":"Rifat","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijtb.2026.03.006_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2021.696525","article-title":"Mycobacterial infection of precision-cut lung slices reveals type 1 interferon pathway is locally induced by Mycobacterium bovis but not M. tuberculosis in a cattle breed","volume":"8","author":"Remot","year":"2021","journal-title":"Front Vet Sci"},{"issue":"12","key":"10.1016\/j.ijtb.2026.03.006_bib14","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.3390\/pharmaceutics14122666","article-title":"Determination of the pharmacokinetics and pharmacodynamics of isoniazid, Rifampicin, pyrazinamide and ethambutol in a cross-over cynomolgus macaque model of Mycobacterium tuberculosis infection","volume":"14","author":"Sibley","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/21505594.2020.1781486","article-title":"A novel biosafety level 2 compliant tuberculosis infection model using a \u0394leuD\u0394panCD double auxotroph of Mycobacterium tuberculosis H37Rv and Galleria mellonella","volume":"11","author":"Asai","year":"2020","journal-title":"Virulence"},{"issue":"12","key":"10.1016\/j.ijtb.2026.03.006_bib16","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3390\/biom13121793","article-title":"Repurposing an antioxidant to kill Mycobacterium tuberculosis by targeting the 50S subunit of the ribosome","volume":"13","author":"Dong","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12906-017-1786-0","article-title":"Thymoquinone (TQ) inhibits the replication of intracellular Mycobacterium tuberculosis in macrophages and modulates nitric oxide production","volume":"17","author":"Mahmud","year":"2017","journal-title":"BMC Compl Alternative Med"},{"issue":"5","key":"10.1016\/j.ijtb.2026.03.006_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02509-22","article-title":"FDA-approved amoxapine effectively promotes macrophage control of mycobacteria by inducing autophagy","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijtb.2026.03.006_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ebiom.2016.02.040","article-title":"A long-term Co-perfused disseminated Tuberculosis-3D liver hollow fiber model for both drug efficacy and hepatotoxicity in babies","volume":"6","author":"Srivastava","year":"2016","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02073-16","article-title":"A bioengineered three-dimensional cell culture platform integrated with microfluidics to address antimicrobial resistance in tuberculosis","volume":"8","author":"Bielecka","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.ijtb.2026.03.006_bib21","first-page":"2023","article-title":"Lung-mimicking 3-Dimensional hydrogel culture system recapitulates key tuberculosis phenotypes and demonstrates pyrazinamide efficacy","author":"Gupta","year":"2023","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/j.ijtb.2026.03.006_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01310-24","article-title":"Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice","volume":"69","author":"Wynn","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib23","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41467-025-56146-9","article-title":"The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis","volume":"16","author":"R\u00f6mpp","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijtb.2026.03.006_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1400436","article-title":"A novel non-invasive murine model for rapidly testing drug activity via inhalation administration against Mycobacterium tuberculosis","volume":"15","author":"Tian","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijtb.2026.03.006_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijid.2016.08.027","article-title":"Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo","volume":"52","author":"Zhao","year":"2016","journal-title":"Int J Infect Dis : Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.ijtb.2026.03.006_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00636-18","article-title":"Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis","volume":"62","author":"Ammerman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijtb.2026.03.006_bib27","first-page":"235","article-title":"Activities of Biapenem against Mycobacterium tuberculosis in macrophages and mice","volume":"32","author":"Guo","year":"2019","journal-title":"Biomedical and environmental sciences : BES (Biomed Environ Sci)"},{"issue":"3","key":"10.1016\/j.ijtb.2026.03.006_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01727-19","article-title":"Mechanistic modeling of Mycobacterium tuberculosis infection in murine models for drug and vaccine efficacy studies","volume":"64","author":"Zhang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijtb.2026.03.006_bib29","first-page":"770","article-title":"Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models","volume":"72","author":"Robertson","year":"2017","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02477-21","article-title":"Sudapyridine (WX-081), a novel compound against Mycobacterium tuberculosis","volume":"10","author":"Yao","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10.1016\/j.ijtb.2026.03.006_bib31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijantimicag.2016.04.029","article-title":"Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection","volume":"48","author":"Rodrigues-Junior","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12974-022-02387-0","article-title":"Nos2-\/- mice infected with M. tuberculosis develop neurobehavioral changes and immunopathology mimicking human central nervous system tuberculosis","volume":"19","author":"Poh","year":"2022","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.ijtb.2026.03.006_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2024.102479","article-title":"The use of Mycobacterium tuberculosis H37Ra-infected immunocompetent mice as an in vivo model of persisters","volume":"145","author":"Kumari","year":"2024","journal-title":"Tuberculosis"},{"issue":"7","key":"10.1016\/j.ijtb.2026.03.006_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158849","article-title":"A mouse model of latent tuberculosis infection to study intervention strategies to prevent reactivation","volume":"11","author":"Kupz","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ijtb.2026.03.006_bib35","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210332","article-title":"Genetic models of latent tuberculosis in mice reveal differential influence of adaptive immunity","volume":"218","author":"Su","year":"2021","journal-title":"The Journal of experimental medicine"},{"key":"10.1016\/j.ijtb.2026.03.006_bib36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.tube.2018.10.003","article-title":"A new model for chronic and reactivation tuberculosis: infection with genetically attenuated Mycobacterium tuberculosis in mice with polar susceptibility","volume":"113","author":"Kondratieva","year":"2018","journal-title":"Tuberculosis"},{"issue":"12","key":"10.1016\/j.ijtb.2026.03.006_bib37","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.3390\/pharmaceutics15122758","article-title":"The pharmacokinetics of CPZEN-45, a novel anti-tuberculosis drug, in Guinea pigs","volume":"15","author":"Garcia-Contreras","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.ijtb.2026.03.006_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/vaccines13030305","article-title":"Bacillus Calmette-Gu\u00e9rin vaccination promotes efficient and comprehensive immune modulation in Guinea pig models","volume":"13","author":"Ouh","year":"2025","journal-title":"Vaccines"},{"issue":"8","key":"10.1016\/j.ijtb.2026.03.006_bib39","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/pharmaceutics13081309","article-title":"Efficacy of combined Rifampicin formulations delivered by the pulmonary route to treat tuberculosis in the Guinea pig model","volume":"13","author":"Garcia-Contreras","year":"2021","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.ijtb.2026.03.006_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02402-16","article-title":"Delamanid kills dormant mycobacteria In Vitro and in a Guinea pig model of tuberculosis","volume":"61","author":"Chen","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijtb.2026.03.006_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01438-22","article-title":"Pharmacokinetics and efficacy of the benzothiazinone BTZ-043 against tuberculous mycobacteria inside Granulomas in the Guinea pig model","volume":"67","author":"Eckhardt","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib42","doi-asserted-by":"crossref","DOI":"10.5312\/wjo.v16.i1.101424","article-title":"Comparative study of a rabbit model of spinal tuberculosis using different concentrations of Mycobacterium tuberculosis","volume":"16","author":"Qiao","year":"2025","journal-title":"World J Orthoped"},{"issue":"5","key":"10.1016\/j.ijtb.2026.03.006_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02516-18","article-title":"Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations","volume":"63","author":"Sarathy","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib44","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/AAC.05208-11","article-title":"Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions","volume":"56","author":"Kjellsson","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ijtb.2026.03.006_bib45","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1242\/dmm.027326","article-title":"Microglia activation in a pediatric rabbit model of tuberculous meningitis","volume":"9","author":"Tucker","year":"2016","journal-title":"Dis Model Mech"},{"issue":"10","key":"10.1016\/j.ijtb.2026.03.006_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00913-19","article-title":"Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans","volume":"63","author":"Tucker","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2026.03.006_bib47","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fcimb.2019.00450","article-title":"Thalidomide and phosphodiesterase 4 inhibitors as host directed therapeutics for tuberculous meningitis: insights from the rabbit model","volume":"9","author":"Kumar","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijtb.2026.03.006_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1246826","article-title":"Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in Guinea pigs but fails to improve on BCG-conferred protection in non-human primates","volume":"14","author":"White","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ijtb.2026.03.006_bib49","doi-asserted-by":"crossref","DOI":"10.1099\/acmi.0.000118","article-title":"Challenges in the veterinary microbiology diagnostic laboratory: a novel Acinetobacter species as presumptive cause for feline unilateral conjunctivitis","volume":"2","author":"Vale","year":"2020","journal-title":"Access microbiology"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41541-024-01009-5","article-title":"MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates","volume":"9","author":"Peralta-\u00c1lvarez","year":"2024","journal-title":"npj Vaccines"},{"issue":"3","key":"10.1016\/j.ijtb.2026.03.006_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171906","article-title":"An aerosol challenge model of tuberculosis in Mauritian cynomolgus macaques","volume":"12","author":"Sharpe","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ijtb.2026.03.006_bib52","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.immuni.2024.08.002","article-title":"CD4+ T cells re-wire granuloma cellularity and regulatory networks to promote immunomodulation following Mtb reinfection","volume":"57","author":"Bromley","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.ijtb.2026.03.006_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1478263","article-title":"Drosophila melanogaster experimental model to test new antimicrobials: a methodological approach","volume":"15","author":"Vidal","year":"2024","journal-title":"Front Microbiol"},{"issue":"12","key":"10.1016\/j.ijtb.2026.03.006_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00448-22","article-title":"Synergistic effect of Q203 combined with PBTZ169 against Mycobacterium tuberculosis","volume":"66","author":"Nguyen","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib55","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1080\/21505594.2022.2119657","article-title":"Galleria mellonella as an infection model for the virulent Mycobacterium tuberculosis H37Rv","volume":"13","author":"Asai","year":"2022","journal-title":"Virulence"},{"issue":"4","key":"10.1016\/j.ijtb.2026.03.006_bib56","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s13205-019-1645-4","article-title":"Understanding lipidomic basis of iron limitation induced chemosensitization of drug-resistant Mycobacterium tuberculosis","volume":"9","author":"Pal","year":"2019","journal-title":"3 Biotech"},{"key":"10.1016\/j.ijtb.2026.03.006_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104262","article-title":"Rec A disruption unveils cross talk between DNA repair and membrane damage, efflux pump activity, biofilm formation in Mycobacterium smegmatis","volume":"149","author":"Hans","year":"2020","journal-title":"Microb Pathog"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib58","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1038\/s41598-019-43201-x","article-title":"Combination of repurposed drug diosmin with amoxicillin-clavulanic acid causes synergistic inhibition of mycobacterial growth","volume":"9","author":"Pushkaran","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib59","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1038\/s41598-017-03477-3","article-title":"Ohmyungsamycins promote antimicrobial responses through autophagy activation via AMP-activated protein kinase pathway","volume":"7","author":"Kim","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.ijtb.2026.03.006_bib60","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.micinf.2013.06.011","article-title":"Drosophila melanogaster model for Mycobacterium abscessus infection","volume":"15","author":"Oh","year":"2013","journal-title":"Microb Infect"},{"issue":"6","key":"10.1016\/j.ijtb.2026.03.006_bib61","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/jac\/dku024","article-title":"Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model","volume":"69","author":"Oh","year":"2014","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"3","key":"10.1016\/j.ijtb.2026.03.006_bib62","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00281-015-0490-8","article-title":"CD8 T cells and Mycobacterium tuberculosis infection","volume":"37","author":"Lin","year":"2015","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.ijtb.2026.03.006_bib63","series-title":"Laboratory Biosafety Manual","year":"2004"},{"issue":"10","key":"10.1016\/j.ijtb.2026.03.006_bib64","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3390\/ani9100754","article-title":"The 3Rs and humane experimental technique: implementing change","volume":"9","author":"Hubrecht","year":"2019","journal-title":"Animals : an open access journal from MDPI"},{"key":"10.1016\/j.ijtb.2026.03.006_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2023.1185706","article-title":"Advancing the 3Rs: innovation, implementation, ethics and society","volume":"10","author":"Grimm","year":"2023","journal-title":"Front Vet Sci"},{"issue":"2","key":"10.1016\/j.ijtb.2026.03.006_bib66","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/ani13020277","article-title":"3Rs principle and legislative decrees to achieve high standard of animal research","volume":"13","author":"Verderio","year":"2023","journal-title":"Animals : an open access journal from MDPI"},{"issue":"1","key":"10.1016\/j.ijtb.2026.03.006_bib67","first-page":"277","article-title":"International standards: the World Organisation for animal health terrestrial animal health code","volume":"34","author":"Thiermann","year":"2015","journal-title":"Revue scientifique et technique (International Office of Epizootics)"},{"issue":"7","key":"10.1016\/j.ijtb.2026.03.006_bib68","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570726000739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570726000739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:04:11Z","timestamp":1776877451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570726000739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0019570726000739"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2026.03.006","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical approaches in tuberculosis drug development research: Bridging experimental tools and clinical translation","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2026.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Tuberculosis Association of India. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}